GH

Musa Tariq

Known title: DirectorCIK: 0001968281

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.

this person other insiders at GH

Transaction History

GH▼ Sell$20K
GH▲ Buy$0
GH▼ Sell$18K
GH▲ Buy$0
GH▼ Sell$19K
GH▲ Buy$0
GH▼ Sell$256K
GH▲ Buy$0
GH▼ Sell$15K
GH▲ Buy$0
GH▼ Sell$11K
GH▲ Buy$0
GH▼ Sell$10K
GH▲ Buy$0
GH▼ Sell$31K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$12K
GH▲ Buy$0
GH▼ Sell$11K
GH▲ Buy$0
GH▼ Sell$8K
GH▲ Buy$0
GH▼ Sell$6K
GH▲ Buy$0
GH▼ Sell$7K
GH▲ Buy$0
GH▼ Sell$6K
GH▲ Buy$0
GH▼ Sell$159K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$5K
GH▲ Buy$0
GH▼ Sell$5K
GH▲ Buy$0
GH▼ Sell$5K
GH▲ Buy$0
GH▼ Sell$6K
GH▲ Buy$0
GH▼ Sell$4K
GH▲ Buy$0
GH▼ Sell$4K
GH▲ Buy$0
GH▼ Sell$81K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.